



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

June 1, 2016

Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) DHS Recommendation Letter – April 2016
 - b) Iowa Medicaid P&T Committee Recommendation to DUR
3. IME Pharmacy Update
4. Updates/News Relevant to Medicaid
5. Prevalence Report Summary
6. Case Studies
7. Public Comment (See Conflict of Interest Disclosure Form)
8. Focus Studies/Provider Education Initiatives
 - a) Members Exceeding Proposed Benzodiazepine Quantity Limits – Follow Up
 - b) Duplicate Beta-Blockers – Follow Up
 - c) Vimpat Dose Greater than 400mg – Follow Up
 - d) Anticholinergics with Second Generation Antipsychotics – Follow Up
 - e) Methadone Utilization – Updated
9. ProDUR Edits
 - a) Tramadol Utilization in Members under 18 years of Age - Updated
10. Prior Authorization
 - a) Topical Acne and Rosacea Products (combination of Topical Anti-Acne Agents and Topical Retinoids) – Initial Review

- b) NOACs (Removal and Combination of Criteria) – Initial Review
- c) Patiromer (Veltassa) – Initial Review
- d) Long-Acting Opioids – Second Review
- e) Adalimumab (Humira[®]) for Hidradenitis Suppurativa – Second Review
- f) Rifaximin (Xifaxan[®]) – Second Review
- g) Ivabradine (Corlanor[®]) – Second Review
- h) Deferasirox – Second Review
- i) Eluxadoline (Viberzi[™]) – Second Review
- j) Mepolizumab (Nucala[™]) – Second Review

11. Miscellaneous

- a) DUR Digest Vol. 28, No. 3 – Second Review
- b) MedWatch

12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting August 3, 2016***
Learning Resource Center, West Des Moines, IA**